R

Retinal Diagnostic Center | Campbell, CA

Research site
(Unclaimed)
Location
3394 S Bascom Avenue, Campbell, California, United States of America
Site insights

Top conditions

Macular Degeneration (15 trials)

Macular Edema (11 trials)

Geographic Atrophy (9 trials)

Atrophy (9 trials)

Edema (9 trials)

Top treatments

Faricimab
APL-2
Lampalizumab
Ranibizumab
Zimura
Avacincaptad pegol
Pegcetacoplan
Triamcinolone Acetonide
Strontium90 Beta
Pemafibrate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 34
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling
Diabetic Retinopathy (DR)
Drug: Topical Steroid
Genetic: RGX-314 Dose 1

Trial sponsors

Roche logo

Roche (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems